Clinical Trial Update: Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%

View source ↗

Summary

The clinical trial evaluating vericiguat in acute coronary syndrome patients with ejection fraction below 45% has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Verquvo (vericiguat)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Acute Coronary Syndrome, Heart Failure With Reduced Ejection Fraction | Status: COMPLETED